Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Embecta Corp. stock logo
EMBC
Embecta
$10.16
-0.6%
$11.14
$9.49
$21.48
$593.31M1.13486,965 shs40,861 shs
Paragon 28, Inc. stock logo
FNA
Paragon 28
$13.11
+0.1%
$13.10
$4.65
$13.13
$1.10B1.471.14 million shs19.38 million shs
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
$5.97
+0.1%
$6.60
$5.47
$10.14
$879.55M1.82677,414 shs59,629 shs
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
$19.14
-5.2%
$20.36
$15.75
$48.24
$1.27B1.521.52 million shs639,189 shs
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Embecta Corp. stock logo
EMBC
Embecta
+4.07%+3.86%-4.66%-18.37%-18.37%
Paragon 28, Inc. stock logo
FNA
Paragon 28
0.00%0.00%0.00%+0.69%+113.61%
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
+0.34%+1.88%-10.11%-21.99%-12.35%
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
-0.20%+0.55%-2.61%+2.64%-49.52%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Embecta Corp. stock logo
EMBC
Embecta
4.0777 of 5 stars
3.21.03.30.00.03.33.8
Paragon 28, Inc. stock logo
FNA
Paragon 28
N/AN/AN/AN/AN/AN/AN/AN/A
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
3.2028 of 5 stars
3.53.00.00.00.03.31.9
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
4.1355 of 5 stars
4.21.00.04.92.90.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Embecta Corp. stock logo
EMBC
Embecta
2.33
Hold$19.3390.29% Upside
Paragon 28, Inc. stock logo
FNA
Paragon 28
2.20
Hold$12.75-2.71% Downside
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
3.00
Buy$12.50109.56% Upside
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
2.40
Hold$33.4374.69% Upside

Current Analyst Ratings Breakdown

Latest EMBC, FNA, MDXG, and TNDM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/16/2025
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageHold$24.00
5/23/2025
Embecta Corp. stock logo
EMBC
Embecta
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$25.00
5/23/2025
Embecta Corp. stock logo
EMBC
Embecta
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$15.00 ➝ $13.00
5/22/2025
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$20.00 ➝ $24.00
5/1/2025
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$58.00 ➝ $59.00
5/1/2025
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$60.00 ➝ $31.00
5/1/2025
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$22.00 ➝ $20.00
5/1/2025
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$36.00 ➝ $30.00
5/1/2025
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$33.00 ➝ $24.00
4/10/2025
Embecta Corp. stock logo
EMBC
Embecta
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$15.00
4/10/2025
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$20.00
(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Embecta Corp. stock logo
EMBC
Embecta
$1.08B0.55$3.46 per share2.94($12.80) per share-0.79
Paragon 28, Inc. stock logo
FNA
Paragon 28
$256.18M4.29N/AN/A$2.05 per share6.39
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
$348.88M2.53$0.33 per share17.93$1.31 per share4.55
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
$982.95M1.30N/AN/A$4.01 per share4.77
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Embecta Corp. stock logo
EMBC
Embecta
$78.30M$0.9011.283.310.624.89%-19.67%12.27%8/8/2025 (Estimated)
Paragon 28, Inc. stock logo
FNA
Paragon 28
-$57.53M-$0.63N/AN/AN/A-25.31%-37.90%-18.22%N/A
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
$42.42M$0.2722.0618.64N/A11.40%22.70%16.77%7/30/2025 (Estimated)
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
-$96.03M-$2.78N/AN/AN/A-18.71%-57.33%-13.48%7/30/2025 (Estimated)

Latest EMBC, FNA, MDXG, and TNDM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2025Q2 2025
Embecta Corp. stock logo
EMBC
Embecta
$0.66$0.70+$0.04$0.40$261.77 million$259.00 million
4/30/2025Q1 2025
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
$0.06$0.06N/A$0.05$86.32 million$88.21 million
4/30/2025Q1 2025
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
-$0.60-$0.67-$0.07-$1.97$220.19 million$234.42 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Embecta Corp. stock logo
EMBC
Embecta
$0.605.91%N/A66.67%N/A
Paragon 28, Inc. stock logo
FNA
Paragon 28
N/AN/AN/AN/AN/A
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
N/AN/AN/AN/AN/A
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
N/AN/AN/AN/AN/A

Latest EMBC, FNA, MDXG, and TNDM Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/5/2025
Embecta Corp. stock logo
EMBC
Embecta
quarterly$0.154.51%5/28/20255/28/20256/13/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Embecta Corp. stock logo
EMBC
Embecta
N/A
2.48
1.83
Paragon 28, Inc. stock logo
FNA
Paragon 28
0.79
3.50
1.60
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
0.09
4.70
4.13
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
1.99
2.30
1.81

Institutional Ownership

CompanyInstitutional Ownership
Embecta Corp. stock logo
EMBC
Embecta
93.83%
Paragon 28, Inc. stock logo
FNA
Paragon 28
63.57%
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
79.15%
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
N/A

Insider Ownership

CompanyInsider Ownership
Embecta Corp. stock logo
EMBC
Embecta
0.42%
Paragon 28, Inc. stock logo
FNA
Paragon 28
15.32%
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
1.70%
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
1.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Embecta Corp. stock logo
EMBC
Embecta
2,10058.44 million58.20 millionOptionable
Paragon 28, Inc. stock logo
FNA
Paragon 28
343,00083.94 million70.89 millionOptionable
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
870147.70 million145.19 millionOptionable
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
2,65066.61 million65.34 millionOptionable

Recent News About These Companies

Tandem Diabetes Care Inc TNDM Company Vitals - U.S. News

New MarketBeat Followers Over Time

Media Sentiment Over Time

Embecta stock logo

Embecta NASDAQ:EMBC

$10.16 -0.06 (-0.59%)
As of 11:35 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.

Paragon 28 stock logo

Paragon 28 NYSE:FNA

$13.10 +0.02 (+0.11%)
Closing price 04/17/2025
Extended Trading
$13.10 0.00 (0.00%)
As of 04/17/2025 05:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Paragon 28, Inc. develops, distributes, and sells foot and ankle surgical systems in the United States and internationally. It offers plating systems, including gorilla plating systems, such as lisfranc, lapidus, lateral column, calcaneus slide, and naviculocuneiform (NC) fusion plating systems; baby gorilla plate-specific screws, navicular fracture plates, and 5th metatarsal hook plates; and silverback plating systems. The company also provides precision guide technology for various procedures consisting of fusion, a procedure to address bunion deformities that fuses two bones on the big toe; first tarsometatarsal arthrodesis; and metatarsal osteotomy for bunion correction, medial column beaming for charcot foot reconstruction, ankle fusion plating, and NC joint arthrodesis. In addition, it offers monster, mini monster, and joust beaming screw systems for use in bone reconstruction, osteotomy, arthrodesis, joint fusion, ligament fixation, fracture repair, and fracture fixation; APEX 3D total ankle replacement systems; and total talus spacers to replace the talus and bone in the ankle that connects the leg and foot. Further, the company provides forefoot or hallux valgus correction systems, including phantom intramedullary nail systems for the treatment of severe hallux valgus; and various orthobiologics comprising bone wedges, grafts, demineralized bone matrices, bone void fillers, synthetic materials, amniotic products, and a biocompatible collagen matrix, as well as PRESERVE bone graft systems for homologous application. Additionally, it offers soft tissue fixation systems, titanium sprayed polyetheretherketone implants, nitinol staple systems, stabilization systems, and curved instruments. The company serves hospitals and ambulatory surgery centers through a network of sales representatives and stocking distributors. Paragon 28, Inc. was founded in 2010 and is headquartered in Englewood, Colorado.

MiMedx Group stock logo

MiMedx Group NASDAQ:MDXG

$5.96 +0.01 (+0.08%)
As of 11:35 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.

Tandem Diabetes Care stock logo

Tandem Diabetes Care NASDAQ:TNDM

$19.14 -1.04 (-5.17%)
As of 11:35 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.